BioNTech Results Presentation Deck

Strong Clinical Execution: On Track To Achieve 2021 Corporate Milestones Eight clinical trial initiations in 2021, including three Phase 2 and five first-in-human studies 4 Randomized Phase 2 Trial Starts 19 ● ● ● ● ● 5+ Trial Updates E ● BNT162b2: Multiple updates Additional data disclosures at SITC*: BNT111 BNT112 • BNT221 (pre-clinical) Corporate Milestones - SITC*: BNT311 BNT312 BNT211 BNT411 * SITC: November 10-14, 2021 - abstract embargo lift Nov. 9, 8 am ET BNT111 ✓BNT113 ✔BNT122 ● BNT311 Q4 2021 NEW 6 First-in-human Phase 1 Trial Starts ✓BNT211 - CARVac (Cell Therapy) BNT221 - NEOSTIM (Cell Therapy) BNT151 - Ribocytokine (mRNA) ✓BNT152+153 - Ribocytokine (mRNA) ● TOPP BNT161: Influenza vaccine (license Pfizer) BNT141 - Ribomab (mRNA) - Q4 2021 BNT142 - Ribomab (mRNA) - 1H 2022 BIONTECH

View entire presentation